Abstract
This chapter elaborates the prevention of herpes simplex virus type 1 fatal dissemination in primates with human transfer factor (TF). The specificity of protection was evaluated by examining efficacy against another herpes group virus infection, Herpesvirus saimiri induced leukemia, in the same species of primate. Dialyzable TF was prepared and purified from the single donor. The studies demonstrate the efficacy of human TF in preventing death from herpes simplex virus type 1 induced fatal infection in an animal model. Pretreatment appeared necessary for protection because no animal survived who did not receive TF at least 3 days prior to challenge. Both animals who demonstrated positive cellular immune responses to HSV-1 after TF therapy and were then challenged, survived without ever being clinically ill. The limited number of animals, however, prevents too general an interpretation of results. The small blood volume of marmosets prevented more numerous determinations of in vitro lymphocyte blastogenesis during the course of TF therapy and disease in the other treatment groups, so only the 3 week pretreatment animals could be studied for conversion prior to viral challenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
